Fresenius Kabi sets up JV for IV generics in Indonesia

20 August 2013

Germany-based Fresenius Kabi, part of the Fresenius Group (FRE: Xetra) has formed a joint venture with PT Soho Global Health, a leading Indonesian pharmaceutical company, acquiring a 51% stake in its PT Ethica Industri Farmasi (EIP) subsidiary.

This joint venture will focus on intravenous generic drugs and infusion solutions, and make Fresenius Kabi the market leader in IV generics in Indonesia, the German firm claims. The parties agreed not to disclose the purchase price. Closing of the transaction is expected in the third quarter of 2013.

Founded in 1946, EIP was the first manufacturer of injectable drugs in Indonesia. The company has a broad product portfolio and extensive experience and expertise in the production and marketing of generic drugs in the Indonesian market. EIP operates a production plant in Jakarta. The product portfolio of the future joint venture generated sales of more than 40 million euros ($53.3 million) last year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK